Renal Final Report - Spring 2021 Cycle 

Patients with moderate to severe chronic kidney disease (CKD) and end stage renal disease (ESRD), who are undergoing hemodialysis, often experience pain and receive an opioid prescription for treatment of their pain. The ability to measure opioid prescription rates is important to help ensure safe opioid use in renal patients. The National Quality Forum (NQF) convened a muti-stakeholder Standing Committee on June 23, 2021, which consisted of 25 individuals. The Committee evaluated and made recommendations for endorsement on two new opioid use measures for patients with kidney disease. Neither of the measures were endorsed.